BetterLife provides update of mechanism of action of BETR-001
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Scientific Update on BETR-001: BetterLife Pharma presented promising preclinical data for its compound BETR-001, which selectively activates the serotonin 5HT2A receptor to treat depression and anxiety without causing hallucinations, unlike traditional psychedelics.
Future Development Plans: BETR-001 is expected to enter human trials in H1 2026, with potential applications for various psychiatric and neurological disorders, while also offering advantages such as no tolerance development and non-controlled substance status for patient self-administration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
